PGE2 differentially regulates monocyte-derived dendritic cell cytokine responses depending on receptor usage (EP2/EP4).

Abstract Dendritic cells (DCs) are central players in coordinating immune responses, both innate and adaptive. While the role of lipid mediators in the immune response has been the subject of many investigations, the precise role of prostaglandins has often been plagued by contradictory studies. In this study, we examined the role of PGE 2 on human DC function. Although studies have suggested that PGE 2 specifically plays a role in DC motility and cytokine release profile, the precise receptor usage and signaling pathways involved remain unclear. In this report we found that irrespective of the human donor, monocyte-derived dendritic cells (MoDCs) express three of the four PGE 2 receptor subtypes (EP 2–4 ), although only EP 2 and EP 4 were active with respect to cytokine production. Using selective EP receptor antagonists and agonists, we demonstrate that PGE 2 coordinates control of IL-23 release (a promoter of Th17, an autoimmune associated T cell subset) in a dose-dependent manner by differential use of EP 2 and EP 4 receptors in LPS-activated MoDCs. This is in contrast to IL-12, which is dose dependently inhibited by PGE 2 through both receptor subtypes. Low concentrations (∼1–10 nM) of PGE 2 promoted IL-23 production via EP 4 receptors, while at higher (>50 nM), but still physiologically relevant concentrations, IL-23 is suppressed by an EP 2 dependent mechanism. These results can be explained by differential regulation of the common subunit, IL-12p40, and IL-23p19, by EP 2 and EP 4 . By these means, PGE 2 can act as a regulatory switch of immune responses depending on its concentration in the microenvironment. In addition, we believe these results may also explain why seemingly conflicting biological functions assigned to PGE 2 have been reported in the literature, as the concentration of ligand (PGE 2 ) fundamentally alters the nature of the response. This finding also highlights the potential of designing therapeutics which differentially target these receptors.